Targeted therapy for systemic lupus erythematosus
- VernacularTitle:系统性红斑狼疮靶向治疗研究进展
- Author:
Ke XUE
1
;
Jia CHEN
1
;
Bin LI
1
Author Information
- Publication Type:Journal Article
- Keywords: Lupus erythematosus, systemic; Targeted treatment; Biologic agent; Clinical trial
- From: Chinese Journal of Dermatology 2025;58(8):781-784
- CountryChina
- Language:Chinese
- Abstract: The exploration of novel targeted therapies for systemic lupus erythematosus (SLE) has always been a research hot topic in China and other countries. In recent years, there has been an increasingly in-depth understanding of the pathogenesis of SLE. The approval of belimumab, telitacicept, and anifrolumab for clinical application marked a breakthrough in the treatment of SLE. In addition, novel agents targeting other B-cell/plasma cell antigens, T cells, neutrophils, and multiple inflammatory signaling pathways are emerging, which may provide more treatment options for SLE. This review summarizes research progress in targeted therapies for SLE based on the latest clinical trials, providing a basis for individualized treatment of SLE.
